I asked ChatGPT to settle the ISA v SIPP debate once and for all. It said…

For the past year there has been a long-running debate about whether it is better to invest in the stock market using a SIPP or an ISA.

The dispute often comes to a head as the ISA’s Dividends and Shares deadline approaches. With 5 April now three weeks away, many will be rushing to contribute to the ISA. However, I think that the Multi-Investment Pension is overlooked and deserves a proper hearing. So which comes out on top?

Given the competing and often confusing tax benefits, I decided to ask ChatGPT to settle the ISA v SIPP debate once and for all.

Competing tax papers

It started by praising ISAs for their simplicity. Money grows without income tax and capital gains tax, and withdrawals are completely tax-free. “Investors can come in whenever they want“, said the chatbot.

It said the main advantage of SIPP is the tax relief on the premiums. Pay £80 and the government top it up to £100, for basic rate taxpayers. Higher rate taxpayers can claim an extra £20 back. That’s a quick return and the tax exemption creates profits and growth, too.

Please note that tax treatment depends on individual circumstances and may change in the future. This article is for information only and does not constitute tax advice. Investors should do their own research and consider seeking professional guidance.

There is a catch. SIPP payments are locked in until you are at least 55, rising to 57 from 2028. Also, withdrawals are taxable. ChatGPT declined to announce an absolute winner. It’s understandable. My view is that it is not an either/or decision. SIPPs and ISAs can work well together. SIPPs give investors tax relief on the way in, ISAs on the way out. Balancing the two gives investors the best of both worlds.

Then comes the fun part – choosing what to plant. This is where I download the ChatGPT services. I wouldn’t trust it to buy stocks, as it is very volatile and makes easy mistakes. Stock picking still requires human ingenuity rather than the artificial variety.

GSK shares look good value

One FTSE 100 The stock that caught my eye is the pharmaceutical giant GSK (LSE: GSK). Its shares have struggled for years as former boss Emma Walmsley invested to rebuild the drug pipeline instead of boosting profits. Investors had to be patient as their payments stopped and the share price went nowhere.

Now the picture is improving. Prior to the recent market crisis, stocks had been rising sharply. GSK’s share price is still up 35% over the past 12 months, and that’s despite falling 7.5% in the last month. I think that could be a buying opportunity for those who missed out on the recent recovery.

The dividend yield is not as high as it used to be. Today, it’s a very modest 3.3%. However, the price-to-earnings ratio of 11.8 suggests a decent value. There are risks. Drug development is expensive, slow, and can fail late in the process. Competition is also fierce, with competitors racing to bring new treatments to market.

Nevertheless, I think GSK is worth considering from a long-term perspective. Due to the recent volatility, I can see many equity growth deals in the FTSE 100 today.